Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A randomized, subject and investigator-blind, placebo-controlled study of CLR325 in chronic stable heart failure patients
2016-001387-12Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2016
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) comparing CLR325 with Placebo (2 arms). Primary endpoint: Safety and tolerability of CLR325. Started May 2016; status: completed.
02
Drugs
CLR325
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on 2016-001387-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001387-12.